Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Want to cut your energy bills? Here’s how five experts are doing it 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
-- Company presentation scheduled for March 7th, 2017 at 9:20 a.m. ET --
SOUTH SAN FRANCISCO, Calif., March 02, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the Cowen and Company 37th Annual Health Care Conference in Boston. Achaogen management will present at 9:20 a.m. Eastern Time on Tuesday, March 7th, 2017.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc.
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
